biostudies-literatureVan der Vreken AGhent UniversityCatharina WeekersKom op tegen KankerWilly GeptsFonds Wetenschappelijk OnderzoekVrije Universiteit BrusselKing Baudouin Foundatione010673https://www.ebi.ac.uk/biostudies/studies/S-EPMC12049997biostudies-literatureUnknown13(4)<h4>Background</h4>Invariant natural killer T (iNKT) cells and CD8⁺ T cells are key in the immune response against multiple myeloma (MM), a largely incurable blood cancer. Immunization is a promising strategy to activate these T cell populations. To our knowledge, immunization with messenger RNA (mRNA) and the iNKT agonist, α-galactosylceramide (αGC), has not been studied in MM, as knowledge on clinically relevant antigens in preclinical MM models is lacking.<h4>Methods</h4>Microarray data and immunopeptidomics (imPep) were used to identify candidate antigens for immunization in 5TMM models. Galsomes, lipid nanoparticles containing antigen mRNA and αGC were used to immunize 5T33MM-bearing mice. This treatment was combined with a CD40 agonist. Tumor burden and activation of iNKT Journal for immunotherapy of cancerImmunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.PMC120499971164918N1S73122N12AN524NFAF-C/2018/12132020-J1811380-217916SRP48G040319N1275023NSRP84WFWG201912I0921NK110324NBOF21/GOA/033BOF/STA/202209/011Mwangi KVanderkerken KTu CVerbeke RMenu EJanssens ELentacker IFranceschini LDe Bruyne EVan der Vreken AThery FImpens FMeulewaeter SBreckpot KDe Beck LDe Veirman KfalseImmunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.<h4>Background</h4>Invariant natural killer T (iNKT) cells and CD8⁺ T cells are key in the immune response against multiple myeloma (MM), a largely incurable blood cancer. Immunization is a promising strategy to activate these T cell populations. To our knowledge, immunization with messenger RNA (mRNA) and the iNKT agonist, α-galactosylceramide (αGC), has not been studied in MM, as knowledge on clinically relevant antigens in preclinical MM models is lacking.<h4>Methods</h4>Microarray data and immunopeptidomics (imPep) were used to identify candidate antigens for immunization in 5TMM models. Galsomes, lipid nanoparticles containing antigen mRNA and αGC were used to immunize 5T33MM-bearing mice. This treatment was combined with a CD40 agonist. Tumor burden and activation of iNKT 2025-01-01T00:00:00Z2025 Apr2026-06-02T17:33:38.206Z2025-07-04T03:06:05.273ZS-EPMC120499974030085510.1136/jitc-2024-010673